EED INTERVENTIONS: PRE- AND PRO-BIOTIC SAFETY Produced by: - - PowerPoint PPT Presentation

eed interventions pre and pro biotic safety
SMART_READER_LITE
LIVE PREVIEW

EED INTERVENTIONS: PRE- AND PRO-BIOTIC SAFETY Produced by: - - PowerPoint PPT Presentation

6/6/2016 EED INTERVENTIONS: PRE- AND PRO-BIOTIC SAFETY Produced by: Dietrich, C.; Kidane, L.; Babigumira, J. EED Interventions | Agenda Agenda Timeline Project Background and Objectives Key Takeaways Approach & Rationale


slide-1
SLIDE 1

EED Interventions

|

EED INTERVENTIONS: PRE- AND PRO-BIOTIC SAFETY

Produced by: Dietrich, C.; Kidane, L.; Babigumira, J.

6/6/2016

slide-2
SLIDE 2

EED Interventions

| ¨ Timeline ¨ Project Background and Objectives ¨ Key Takeaways ¨ Approach & Rationale ¨ Methods ¨ Results ¨ Discussion and Next Steps

Agenda

Agenda

6/6/2016

slide-3
SLIDE 3

EED Interventions

|

Timeline

Timeline

6/6/2016

= Check-In Point

  • Confirm work plan

and scope

  • Strategize

approach

Landscape Analysis

  • Review relevant literature &

extract data

  • Relay initial findings & finalize results

Scoping

slide-4
SLIDE 4

EED Interventions

|

Project Background and Objectives

6/6/2016

The Enteric and Diarrheal Disease Team of the Bill & Melinda Gates Foundation previously engaged the START team to conduct a landscape analysis of intervention trials for Environmental Enteric Dysfunction (EED). During the course of this analysis, an additional but parallel track of work was identified to do a similar landscape analysis for pre- and pro- biotic interventions for growth faltering that may be caused by EED. Background To examine pre- and pro-biotic interventions Diagnosis of EED by gut biopsy is an invasive and resource-intensive process and is often not feasible in vulnerable populations. Having previously focused on EED biomarkers in Phase I, outcomes of interest for this review include safety and efficacy endpoints for pre- and pro- biotic use in infants and children. Objectives

Work Order to the UW START Team

slide-5
SLIDE 5

EED Interventions

|

¨ Very few studies conducted in LMICs ¨ Bifidobacteria and Lactobacillus are the most common genus of

bacteria studied; GOS, most common prebiotic

¨ Majority of studies demonstrated no differences in SAEs, adverse

events and tolerability between interventions and controls

¤ If there were differences, typically pre- and pro-biotics had positive

effects

¨ Difficult to detect significant growth changes in healthy children

Key Takeaways

Takeaways

6/6/2016

slide-6
SLIDE 6

EED Interventions

| ¨ Focus on the inclusion of a stunting measures such

as growth velocity or LAZ

¨ Probiotic or prebiotic as an intervention, no

  • bservational studies

¨ Expanded to populations beyond LMICs ¨ Analyze safety and efficacy of probiotics in

children

¤ Adverse events ¤ Infection

Probiotic and Prebiotic Safety with Stunting Endpoints

Approach & Rationale

6/6/2016

slide-7
SLIDE 7

EED Interventions

|

Phase 1 efficacy and safety

¨ Database: Embase ¨ 'phase 1 trial'/exp OR 'phase 1 trial' OR 'safety' OR 'safety'/exp OR safety

OR ('safety' OR 'safety'/exp OR safety AND efficacy) AND ('probio<c'/exp OR 'probio<c' OR 'prebio<c'/exp OR 'prebio<c' OR 'lactobacillus'/exp OR 'lactobacillus' OR 'vsl3'/exp OR 'vsl3' OR 'bacillus'/exp OR 'bacillus' OR 'bifidobacterium'/exp OR 'bifidobacterium' OR 'escherichia coli nissle 1917' OR 'e. coli nissle 1917' OR 'streptococcus thermophilus'/exp OR 'streptococcus thermophilus' OR 'saccharomyces'/exp OR 'saccharomyces') AND ([newborn]/lim OR [infant]/lim OR [child]/lim OR [preschool]/lim OR [school]/lim) AND [humans]/lim AND [english]/lim

¨ 403 hits

Targeted Database and Search

Methods

6/6/2016

slide-8
SLIDE 8

EED Interventions

| ¨ Prospective studies investigating

prebiotics and probiotics

¨ Human Subjects ¨ Children <18 ¨ Safety and efficacy trials

¤ Key words: tolerability, safety,

adverse events

¤ Bactermia or microbiome related

to potentially harmful bacteria

¨ Prioritized: Growth

measurements

¨ Retrospective studies, editorials

and reviews

¨ Animal models/in vitro studies ¨ Adults, including provision to

pregnant mothers

¨ Combination interventions

¤ E.g. Abx+probiotics

¨ Oral health, potentially non-

ingested

¨ No indication of safety other

than non-stunting endpoint Inclusion Exclusion

Inclusion and Exclusion Criteria

6/6/2016

Methods

slide-9
SLIDE 9

EED Interventions

|

Literature Review Flowchart

6/6/2016

Title Review (n=403) Full Text Review (n=110) Prioritized Articles (n=25) Abstract Review (n=214) Exclusions (n=189) Exclusions (n=104)

Embase Search Results:

  • ~27% of titles originally

qualified for full text review

  • Prioritized abstracts with growth

measurements

Methods

Exclusions (n=4)

slide-10
SLIDE 10

EED Interventions

|

Ages Represented

Results

6/6/2016

2 4 6 8 10 12 14

In Utero - Birth Birth - ≤4 weeks 1 - 2 months 3 - 6 months 6 - 12 months 1 - 4 years

Earliest age of enrollment in trials

slide-11
SLIDE 11

EED Interventions

|

Prebiotics Covered

Results

6/6/2016

Galacto-oligosaccharide (GOS) Combo prebiotic short-chain fructo-oligosaccharides (scFOS) Combo prebiotic with LCPUFA Fructo-

  • ligosaccharides

LCPUFA GOS-scFOS

slide-12
SLIDE 12

EED Interventions

|

Probiotics Covered

Results

6/6/2016

Bifidobacterium animalis ssp. lactis Bifidobacterium breve Bifidobacterium infantis Bifidobacterium lactis Bifidobacterium longum Lactobacillus fermentum Lactobacillus paracasei Lactobacillus reuteri Lactobacillus rhamnosus Lactobacillus rhamnosus GG Lactobacillus salivarius Propionibacterium freudenreichii Streptococcus thermophilus

Bifidobacterium Lactobacillus Propionibacterium Streptococcus

slide-13
SLIDE 13

EED Interventions

|

Serious Adverse Events

Results

6/6/2016

6 1 4 8 2

Studies: Serious Adverse Events

None related to study formula No sepsis detected related to probiotic

  • rganisms

Mentioned SAEs but not explicit on relationship to study formulas Not reported Related to Study Formula

slide-14
SLIDE 14

EED Interventions

|

Infections

Results

6/6/2016

Intervention Resulted in Significant Positive Result for Infections or Infection- related Endpoints Antibiotics

  • B. lactis; Streptococcus thermophilus
  • B. breve + Combo prebiotic

LGG + B. breve + Propionibacterium + GOS Drugs for functional GI disorders

  • B. breve + Combo prebiotic

GI infection

  • L. fermentum + GOS

Infection Combo prebiotic + B. breve Intervention Resulted in Significant Negative Result for Infections or Infection-related Endpoints Respiratory infections

  • L. Salivarius
  • 7 studies reported non-significant

differences in a variety of infectious

  • utcomes
  • 2 NEC; 3 GI related
  • 4 Abx, 4 Respiratory infections
  • Otitis media, mean titres for

anti-bodies, hospitalization

slide-15
SLIDE 15

EED Interventions

|

Vomiting

  • Bifidobacterium lactis

Colic & Irritability

  • Bifidobacterium lactis & Streptococcus thermophilus

Loose stools

  • Oligofructose, & Long-chain inulin

Rash

  • GOS, Lactobacillus paracasei, Bifidobacterium animalis ssp. lactis

Adverse Events: General

Results

6/6/2016

slide-16
SLIDE 16

EED Interventions

|

Adverse Events: Diarrhea

Results

6/6/2016

  • Bifidobacterium breve
  • chicory-derived neutral oligofructose, long-chain inulin, & pectin-

derived acidic oligosaccharide (pAOS)

Relative Risk

  • Bifidobacterium longum
  • Lactobacillus rhamnosus
  • Inulin & Fructo-oligosaccharide
  • LCPUFA

Episodes

  • Lactobacillus salivarius

Frequency

slide-17
SLIDE 17

EED Interventions

|

  • Bifidobacterium lactis
  • Oligosaccharide, Lactobacillus rhamnosus,

Bifidobacterium longum

  • Oligosaccharide, Lactobacillus rhamnosus, &

Bifidobacterium longum

  • scFOS
  • Oligosaccharide, Lactobacillus rhamnosus,

Bifidobacterium longum

Tolerability: General

Results

6/6/2016

Mean daily volume of formula intake Colic Frequency of vomiting Green stool Yellow stool

slide-18
SLIDE 18

EED Interventions

|

  • Bifidobacterium longum, Lactobacillus rhamnosus, GOS/scFOS
  • BMOS, Lactobacillus rhamnosus, Bifidobacterium longum
  • Bifidobacterium longum, GOS, Fructo-oligosaccharides
  • Lactobacillus paracasei, Bifidobacterium animalis, GOS
  • Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve,

Propionibacterium freudenreichii spp shermanii JS, GOS

Tolerability: Stool Frequency

Results

6/6/2016

slide-19
SLIDE 19

EED Interventions

|

Tolerability: Improved Stool Consistency

Results

6/6/2016

  • Bifidobacterium longum, Lactobacillus rhamnosussc, FOS
  • Oligosaccharide, Lactobacillus rhamnosus, Bifidobacterium longum
  • GOS
  • Lactobacillus paracasei, Bifidobacterium animalis, GOS
  • scFOS
slide-20
SLIDE 20

EED Interventions

| ¨ Hosni et al, 2012

¤ Extremely low-birth-weight infants ¤ Enteral feeding ¤ LGG - 500 million CFU + Bifidobacterium infan:s - 500 million CFU ¤ Growth velocity: 14.9 ± 6.5 g/day vs. 12.6 ± 4.5 g/day (p=0.05)

¨ Hays et al, 2015

¤ LBW infants (GA between 25 and 31 weeks, birthweight: 700-1600 g) ¤ Bifidobacterium lac:c; Bifidobacterium longum; or combina<on ¤ No significant differences in LAZ, WAZ, weight gain or head circumference in

comparison with those in the control group

Length and Weight Results - LBW

Results

6/6/2016

slide-21
SLIDE 21

EED Interventions

| ¨ Non-significant differences across the majority

  • f studies, as expected

¨ Firmansyah et al, 2011

¤ Change in WAZ – ITT (12 to 16 months) ¤ Syn: 0.11 ± 0.40 vs. Ctl: 0.02 ± 0.40

¨ Gil-campos et al, 2011

¤ LAZ: p=0.021; Syn higher than Ctl w/ Pre (curves shown in Fig. 3) ¤ Length gain (cm/day): Syn higher than Ctl w/ Pre p = 0.038

Length and Weight Results – Healthy Infants

Results

6/6/2016

slide-22
SLIDE 22

EED Interventions

|

GOS

Bifidobacteria Lactobacilli

scFOS

Bifidobacteria

scFOS

Bifidobacteria Lactobacilli

Microbiota Composition

Results

6/6/2016

  • B. lactic and B. longum

Bifidobacterium spp

  • B. longum, L. rhamnosus,

Inulin, & FOS

Lactobacilli/ Enterococci

  • L. salivarius

Lactobacilli Enterobacteria Clostridia Bacteroides

slide-23
SLIDE 23

EED Interventions

|

Microbiota Composition

Results

6/6/2016

Oligofructose

Bifidobacterium Enterobacteriaceae

  • B. breve and

prebio<c combo

Bifidobacterium

  • C. histolyticum
  • E. rectale /C.

coccoides

BMOS

Bifidobacteria Lactobacilli Clostridia

slide-24
SLIDE 24

EED Interventions

|

Discussion and Next Steps

6/6/2016

slide-25
SLIDE 25

EED Interventions

|

Timeline

Timeline

6/6/2016

= Check-In Point

  • Confirm work plan

and scope

  • Strategize

approach

Landscape Analysis

  • Review relevant literature &

extract data

  • Relay initial findings & finalize results

Scoping